[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@Immuneering Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::78703821.png) @Immuneering Immuneering Corp

Immuneering Corp posts on X about $imrx, live from, promising, vienna the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::78703821/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::78703821/c:line/m:interactions.svg)

- X Month XXXXX +49%
- X Months XXXXX +355%
- X Year XXXXX +1,767%

### Mentions: X [#](/creator/twitter::78703821/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::78703821/c:line/m:posts_active.svg)

- X Month X +167%
- X Months XX +100%
- X Year XX +500%

### Followers: XXX [#](/creator/twitter::78703821/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::78703821/c:line/m:followers.svg)

- X Month XXX +19%
- X Months XXX +39%
- X Year XXX +48%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::78703821/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::78703821/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::78703821/influence)
---

**Social category influence**
[exchanges](/list/exchanges)  XXXX% [travel destinations](/list/travel-destinations)  XXXX% [stocks](/list/stocks)  XXXX%

**Social topic influence**
[$imrx](/topic/$imrx) #4, [live from](/topic/live-from) 9.09%, [promising](/topic/promising) 9.09%, [vienna](/topic/vienna) 9.09%, [momentum](/topic/momentum) 9.09%, [$200m](/topic/$200m) 9.09%, [$25m](/topic/$25m) 9.09%, [sanofi](/topic/sanofi) XXXX%

**Top accounts mentioned or mentioned by**
[@nasdaqexchange](/creator/undefined) [@biotechtv](/creator/undefined) [@forbes](/creator/undefined) [@thealexknapp](/creator/undefined) [@benzeskind](/creator/undefined) [@bradloncar](/creator/undefined) [@immuneerings](/creator/undefined) [@targetedonc](/creator/undefined) [@sdbjnews](/creator/undefined) [@pharmexec](/creator/undefined) [@mainz058](/creator/undefined) [@mrgat23](/creator/undefined)

**Top assets mentioned**
[Sanofi (SNY)](/topic/sanofi)
### Top Social Posts [#](/creator/twitter::78703821/posts)
---
Top posts by engagements in the last XX hours

"Were proud to be a 2025 #ScripAwards finalist as Best Oncology R&D Advance for our Phase 2a trial of atebimetinib in pancreatic cancer This honor reflects our commitment to advancing new treatments that aim to help patients live longer & feel better. #Oncology #CancerResearch"  
[X Link](https://x.com/Immuneering/status/1975592073454616846) [@Immuneering](/creator/x/Immuneering) 2025-10-07T16:00Z XXX followers, XXX engagements


"$IMRX and @BenZeskind were honored to join @bradloncar and @BiotechTV live from the NYSE to discuss our latest progress in oncology including promising pancreatic cancer data and our deep cyclic inhibitors. Watch the full video here:"  
[X Link](https://x.com/Immuneering/status/1976672755870564604) [@Immuneering](/creator/x/Immuneering) 2025-10-10T15:34Z XXX followers, XXX engagements


"Meet us in Vienna during #BIOEurope taking place Nov 3-5 Our CBO E.B. Brakewood will be onsite to meet with global business leaders and industry experts in the biotech & pharma fields. Learn more about $IMRX and our pipeline:"  
[X Link](https://x.com/Immuneering/status/1977766482768519636) [@Immuneering](/creator/x/Immuneering) 2025-10-13T16:00Z XXX followers, XXX engagements


"Our clinical data featured in @TargetedOnc highlight the potential of our investigational therapy atebimetinib in combination with chemotherapy to help address pancreatic cancer an area of urgent unmet need"  
[X Link](https://x.com/Immuneering/status/1976316772262244554) [@Immuneering](/creator/x/Immuneering) 2025-10-09T16:00Z XXX followers, XXX engagements


"ICYMI: $IMRX ended Sept. with strong momentum: XX% 9-month survival in 1L pancreatic cancer (atebimetinib + mGnP) and a $200M financing including $25M from Sanofi. Webcast replay:"  
[X Link](https://x.com/Immuneering/status/1978481083717927224) [@Immuneering](/creator/x/Immuneering) 2025-10-15T15:20Z XXX followers, XXX engagements